Stratec
XTRA:SBS
17,50
+ €0,40 (2,34%)
17,50
+€0,40 (2,34%)
End-of-day quote: 04/01/2026

Stratec Stock Value

The current analyst rating for Stratec is Buy.
Buy
Buy

Stratec Company Info

EPS Growth 5Y
-4,79%
Market Cap
€0,21 B
Long-Term Debt
€0,07 B
Quarterly earnings
04/28/2026
Dividend
€0,61
Dividend Yield
3,51%
Founded
1979
Industry
Country
Website
ISIN Number

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

€29,00
65.71%
65.71
Last Update: 04/02/2026
Analysts: 5

Highest Price Target €34,00

Average Price Target €29,00

Lowest Price Target €23,00

In the last five quarters, Stratec’s Price Target has fallen from €63,14 to €41,00 - a -35,06% decrease. Five analysts predict that Stratec’s share price will increase in the coming year, reaching €29,00. This would represent an increase of 65,71%.

Top growth stocks in the health care sector (5Y.)

What does Stratec do?

STRATEC SE operates designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences. Business Segments The company operates primarily in the realm of medical technology through multiple business segments. Each segment is meticulously designed to respond to the unique needs of various client categories within the diagnostics industry. The first segment encompasses the engineering and industrialization of advanced laboratory automation sy...
×